TransCode Therapeutics, Inc., (RNAZ): Price and Financial Metrics


TransCode Therapeutics, Inc., (RNAZ): $1.83

0.03 (+1.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RNAZ to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RNAZ Stock Price Chart Interactive Chart >

Price chart for RNAZ

RNAZ Price/Volume Stats

Current price $1.83 52-week high $7.00
Prev. close $1.80 52-week low $1.52
Day low $1.75 Volume 58,200
Day high $1.90 Avg. volume 25,971
50-day MA $2.58 Dividend yield N/A
200-day MA $2.64 Market Cap 23.75M

TransCode Therapeutics, Inc., (RNAZ) Company Bio


TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.


RNAZ Latest News Stream


Event/Time News Detail
Loading, please wait...

RNAZ Latest Social Stream


Loading social stream, please wait...

View Full RNAZ Social Stream

Latest RNAZ News From Around the Web

Below are the latest news stories about Transcode Therapeutics Inc that investors may wish to consider to help them evaluate RNAZ as an investment opportunity.

TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio

BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced that it has filed an International PCT Application (PCT/US21/65580) entitled TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY (the ‘580 application). The ‘580 application, expected to publish in June 2022, represents an extension of TransCode’s use of its patented RNA therapeutic platform to include using patter

Yahoo | February 14, 2022

CORRECTION --TransCode Therapeutics

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE" earlier today by TransCode Therapeutics, Inc. (Nasdaq: RNAZ), please note that in the headline, the date of the conference should be 2022, not 2020 as previously stated. The corrected release follows: TransCode Therapeutics to Present at 2022 BIO CEO & INVESTOR CONFERENCE TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will

Yahoo | February 10, 2022

TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes has the potential to significantly advance the treatment of cancer, including the company’s lead therapeutic candidate designed to treat metastatic disease. The Company is planning to file an explo

Yahoo | February 10, 2022

TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer. The Company plans to advance its lead therapeutic candidate, designed to treat metastatic disease, into its First in Human clini

Yahoo | January 6, 2022

TransCode Therapeutics To Participate at MedInvest Oncology Investor Conference

BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the MedInvest Oncology Investor Conference. TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company’s lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its F

Yahoo | December 7, 2021

Read More 'RNAZ' Stories Here

RNAZ Price Returns

1-mo -32.97%
3-mo -16.06%
6-mo -37.33%
1-year N/A
3-year N/A
5-year N/A
YTD -27.95%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6079 seconds.